Gainers

• Psyence Biomedical (NASDAQ:PBM) shares rose 82.6% to $13.88 during Monday's pre-market session. The company's market cap stands at $7.7 million.
• Enveric Biosciences (NASDAQ:ENVB) shares increased by 79.12% to $3.26. The market value of their outstanding shares is at $2.5 million.
• Theriva Biologics (AMEX:TOVX) shares increased by 78.11% to $0.46. The market value of their outstanding shares is at $11.8 million.
• Artelo Biosciences (NASDAQ:ARTL) shares moved upwards by 69.59% to $7.53. The company's market cap stands at $4.1 million.
• Clearmind Medicine (NASDAQ:CMND) shares increased by 51.47% to $1.09. The company's market cap stands at $1.7 million.
• AtaiBeckley (NASDAQ:ATAI) shares increased by 26.79% to $5.11. The market value of their outstanding shares is at $1.4 billion.

Losers

• AnaptysBio (NASDAQ:ANAB) shares declined by 28.9% to $48.0 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion.
• Passage Bio (NASDAQ:PASG) shares fell 27.77% to $8.43. The company's market cap stands at $37.0 million.
• SBC Medical Group Holding (NASDAQ:SBC) stock decreased by 26.28% to $3.31. The company's market cap stands at $460.5 million.
• CEL-SCI (AMEX:CVM) shares fell 18.79% to $4.02. The market value of their outstanding shares is at $41.8 million.
• Jupiter Neurosciences (NASDAQ:JUNS) shares declined by 17.66% to $0.36. The market value of their outstanding shares is at $15.8 million.
• Modular Medical (NASDAQ:MODD) stock fell 16.39% to $4.9. The company's market cap stands at $27.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.